Product logins

Find logins to all Clarivate products below.


Irritable Bowel Syndrome – Epidemiology – Extrapolated Worldwide Coverage

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key irritable bowel syndrome patient populations, covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.

Use the Extrapolated Worldwide Coverage dashboard to do the following:

  • View 10-year forecasts of the total prevalent cases for all 171 countries, stratified by region and World Bank income status.
  • Aggregate country-level estimates into region-level estimates according to user preference or as required by regulators for orphan drug designations.
  • Visualize global correlations between disease risk or size of patient population and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
  • Generate and export global heat maps of disease risk or size of patient population.

The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available for purchase by clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact Clarivate.support@clarivate.com.

Related Market Assessment Reports

Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms – Claims Data Analysis – IBS-Diarrhea (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. The disorder is grouped into three…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
Report
Crohn’s Disease – Access & Reimbursement – Access & Reimbursement – Crohn’s Disease (US)
TNF-α inhibitors, such as J&J Innovative Medicine’s Remicade and AbbVie’s Humira, remain firmly established in the U.S. Crohn’s disease (CD) treatment landscape. However, therapies with…